CN1939264A - Oral preparation containing ceftazidime and its making method - Google Patents
Oral preparation containing ceftazidime and its making method Download PDFInfo
- Publication number
- CN1939264A CN1939264A CN 200610152610 CN200610152610A CN1939264A CN 1939264 A CN1939264 A CN 1939264A CN 200610152610 CN200610152610 CN 200610152610 CN 200610152610 A CN200610152610 A CN 200610152610A CN 1939264 A CN1939264 A CN 1939264A
- Authority
- CN
- China
- Prior art keywords
- ceftazidime
- substrate
- buccal
- sodium
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
An orally absorbed medicine in the form of buccal lozenge, sweets, or dripping pill dissolved by saliva features that it contains ceftazidime. Its preparing process is also disclosed.
Description
[technical field] the present invention relates to a kind of medicine and preparation method thereof, particularly contains buccal lozenge of ceftazidime and preparation method thereof.
[background technology]
Pharyngitis is the modal disease of puzzlement modern life, is pharyngeal mucous membrane, submucous tissue and adenoid diffuse inflammation, often is the part of upper respiratory tract infection.Be divided into acute and chronic two kinds clinically.Acute pharyngitis is many in autumn and winter and morbidity at the end of winter and the beginning of spring.Pathological changes ordinary wave and whole pharyngeal cavity also can limit to a place.Can cause by virus, antibacterial and physical chemical factor and high temperature, dust, fumagine, irritative gas etc.Bacterial infection is based on gram-positive coccis such as streptococcus, staphylococcus and Diplococcus pneumoniaes.Wherein serious with A group group B streptococcus causer, antibacterial or toxin enter blood, can cause the purulent lesion of organ at a distance, are called acute septic pharyngitis.Treat with oral or injection antibiotics control infection.
The chronic pharyngitis course of disease is very long, and the symptom stubbornness is often by due to the local infection or general pathological changes secondary, with chronic pathological changes repeatedly acute attack be its characteristics, in many cases, acute attack is to be caused by bacterial infection, therefore, suitable antibacterial therapy helps to control acute symptom.
Acute tonsillitis is a kind of non-specific acute inflammation of very common palatine tonsil, often with to a certain degree pharyngeal mucous membrane and swallow adenoid acute inflammation.Main pathogenic bacterium are streptococcus, staphylococcus, Diplococcus pneumoniae.Adenovirus also can cause primary disease.Antibacterial and virus mixed infection are quite a few to be seen.Antibacterial may be extraneous the intrusion, also may be the antibacterial that is hidden in the tonsillar crypts, when Abwehrkraft des Koepers because of cold, humidity, overworked, have a delicate constitution, tobacco and wine are excessive, when factors such as harmful gas stimulation reduce suddenly, due to bacterial reproduction is strengthened.Acute tonsillitis is acute attack repeatedly on chronic tonsil basis often.Clinical manifestation aversion to cold, hyperpyrexia, pharyngalgia, aggravation etc. when swallowing can the concurrent rheumatic fever relevant with hemolytic streptococcal infection, multiple general diseases such as acute glome-rulonephritis, myocarditis, arthritis.Treatment adopts pain relieving to bring down a fever, oral or injection antibiotics control infection.
Treat pharyngitis, tonsillitis and oral cavity infection that bacterial infection causes, often select the antibiotics of resisting gram-positive bacteria for use, the antibiotics of the anti-gram negative bacteria of part also has therapeutical effect.Ceftazidime is a third generation cephalosporin class antibiotic.Enterobacteriaceae lactobacteriaceae such as escherichia coli, pneumobacillus and hemophilus influenza, Pseudomonas aeruginosa etc. there is the height antibacterial activity.Nitrate-negative bacillus, Bacillus alcaligenes etc. also there is good antibacterial action.Highly stable for bacteriogenic most of beta lactamases, so it still can have an antibacterial activity to multiple antibiotic resistant strain in the above-mentioned gram negative bacilli.Gram positive coccus such as streptococcus pneumoniae, Hemolytic streptococcus is extremely sensitive to this product, but this product is only had a moderate activity to staphylococcus, and enterococcus and methicillin-resistant staphylococcus are then often to this product drug resistance.This product is to certain antibacterial activities of anaerobe tool such as dyspepsiacoccus and peptostreptococcuses, but poor to the bacteroides fragilis antibacterial action.Its mechanism of action is to combine with penicillin-binding protein (PBPs) on the bacterial cell membrane, makes the transpeptidase acidylate, suppresses in the antibacterial synthetic every with cell wall; the intersection that influences the cell wall mucopeptide composition links; cell division and growth are suppressed, and ne ar is elongated, dissolving at last and dead.Be used for respiratory tract infection, urinary tract, biliary tract infection due to the responsive pathogenic bacterium, and abdominal cavity infection, pelvic infection, skin soft-tissue infection, bone and the infection of joint, septicemia etc. and average of operation periods infection mitigation.The preparation of having succeeded in developing of this medicine has injection etc., adopts injection to wait the whole body administration.Be easy to cause the local pain reaction when using inconvenience, administration in view of injection, injection simultaneously dilutes medicine by the whole body distribution after entering blood in blood, make medicine lower at the blood drug level of diseased region, and the time that reaches effective blood drug concentration at diseased region is also longer, influences its effective antibacterial efficacy.Therefore, the development buccal lozenge by the oral cavity buccal, directly acts on diseased region with high concentration medicine, is used for pharyngitis, pharyngoamygdalitis and oral cavity infection treatment of diseases, can overcome above-mentioned shortcoming, and strong auxiliary treatment means is provided.
[summary of the invention]
The purpose of this invention is to provide a kind of is the buccal lozenge and preparation method thereof of ingredient with the ceftazidime, and the medicine through port is contained in the intraoral saliva and dissolves, and enters around the oral cavity, pharyngeal and pharyngeal tonsil position, brings into play its antibacterial action.
For achieving the above object, the present invention has adopted following technical scheme:.
The buccal lozenge that contains ceftazidime of the present invention is meant by ingredient that contains ceftazidime and substrate composed preparation, its Chinese medicine: substrate=1: 1-1: 30, through port intracavity and sublingual administration administration are used for the treatment of pharyngitis, pharyngoamygdalitis and oral cavity infection clinically.
Wherein, selected ceftazidime is chemical compound and its esters (as sodium salt, potassium salt, hydrochlorate, sulfate, hydrobromate, tartrate, the fumarate etc.) derivant with following feature:
Chinese: ceftazidime
English by name: Ceftazidime
Formal name used at school is: (6R, 7R)-7-[[(2-amino-4-thiazolyl)-[(1-carboxyl-1-methyl ethoxy) imino group] acetyl group] amino]-2-carboxyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-3-picoline inner salt pentahydrate
Molecular formula: C
22H
22N
6O
7S
25H
2O
Molecular weight: 636.65
Wherein said substrate is the preparation adjuvant that is grouped into by one or more one-tenth, comprising:
1, diluent (filler): for example Icing Sugar, gelatin, glycerol, arabic gum, starch, dextrin, lactose, glucose, mannitol, calcium sulfate, calcium hydrogen phosphate, tricalcium phosphate, gelatinized corn starch, syrup, maltose, gelatine size, cellulose, Kaolin, sodium chloride, modified starch (Sta-RX1500), microcrystalline Cellulose etc., wherein Icing Sugar has sucrose, maltose, dextrinose, dextrinose oligosaccharide, panose, cottonseed sugar, stachyose, oligofructose, fructose, inulin, protein sugar, stevioside, xylitol, maltose alcohol, sorbitol;
2, binding agent: for example water, ethanol, starch, gelatin, sucrose, glucose, dextran, syrup, lactose, arabic gum, sodium alginate, gelatine size, polyvinylpyrrolidone, Polyethylene Glycol, methylcellulose, carboxymethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, maltose, sucrose dextrin copolymer;
3, disintegrating agent: for example starch (corn and potato starch), cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, pectin, carboxymethyl cellulose, microcrystalline Cellulose, tween 80, sodium laurylsulfate, stearyl alcohol sodium sulfonate, kaolin.
4, lubricant: for example stearic acid, calcium stearate, magnesium stearate, zinc stearate, hydrogenated vegetable oil, polyoxyethylene monostearate, light mineral oil, liquid paraffin, boric acid, sodium chloride, sodium benzoate, sodium acetate, enuatrol, sodium laurylsulfate (magnesium), single Laurel sucrose acid ester, adipic acid, fumaric acid, three triacetins, Polyethylene Glycol
1500～20000
5, fluidizer: for example starch, purified talc, differential silica gel, pyrolytic silicon dioxide, hydrated sodium aluminosilicate.
6, slow releasing agent: for example hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, carbomer 934 P, carbomer 971P, carbomer 974P, stearic acid, hexadecanol, octadecanol, ethyl cellulose, zein etc.
7, other: conventional coloring agent, correctives, spice, as aspartame etc.
Described preparation type includes but not limited to buccal tablet, drop pill, confection, capsule, tablet.
The present invention relates to contain the tablet of following composition:
Described tablet is made up of ingredient that includes ceftazidime and substrate, and wherein said substrate contains following material (accounting for the percentage by weight of substrate total amount): diluent 1-100%; Binding agent 0-30%; Disintegrating agent 0-20%; Lubricant 0-20%; Fluidizer 0-20%; Slow releasing agent 0-10% and conventional coloring agent, correctives, spice.
The present invention relates to contain the capsule of following composition:
Described capsule is made up of ingredient that includes ceftazidime and substrate, and wherein said substrate contains following material (accounting for the percentage by weight of substrate total amount): diluent 1-100%; Binding agent 0-30%; Disintegrating agent 0-20%; Lubricant 0-20%; Fluidizer 0-20%; Slow releasing agent 0-10% and conventional coloring agent, correctives, spice.
The present invention relates to contain the drop pill of following composition:
Described drop pill is made up of ingredient that includes ceftazidime and substrate, adopt water-bath, oil bath or other mode of heating, mixed material is heated to fusion, stir, insert on the drop pill machine with suitable speed, splash in 40 →-15 ℃ the condensing agent liquid paraffin, methyl-silicone oil, vegetable oil any one or a few, drying forms, and its mesostroma is by containing Polyethylene Glycol
(2000,4000,6000,8000,10000,20000), one or more one-tenth in polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, stearic acid, sodium stearate, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyethers and the medicinal slow release agent are grouped into.
The present invention relates to contain the buccal tablet of following composition:
Described buccal tablet is made up of ingredient that includes ceftazidime and substrate, and wherein said substrate contains following material (accounting for the percentage by weight of substrate total amount): diluent 1-100%; Binding agent 0-30%; Disintegrating agent 0-20%; Lubricant 0-20%; Fluidizer 0-20%; Slow releasing agent 0-10% and conventional coloring agent, correctives, spice.
The present invention relates to contain the confection of following composition:
Described confection is made up of ingredient that includes ceftazidime and substrate, and wherein said substrate contains following material (accounting for the percentage by weight of substrate total amount): diluent 1-100%; Binding agent 0-20%; Disintegrating agent 0-10%; Lubricant 0-10%; Fluidizer 0-10%; Slow releasing agent 0-10% and conventional coloring agent, correctives, spice.
Preparation method of the present invention comprises following order and step, but following be not limitation of the invention:
1. the preparation method of buccal tablet: proportionally ceftazidime is mixed with substrate; When described substrate was Icing Sugar, described buccal tablet contained but is not limited to one or more composition in sucrose, maltose, dextrinose, dextrinose oligosaccharide, panose, cottonseed sugar, stachyose, oligofructose, glucose, fructose, lactose, inulin, protein sugar, stevioside, xylitol, maltose alcohol, sorbitol, gelatinized corn starch, syrup, the maltose etc.; When described substrate was solvent, described buccal tablet contained but is not limited to Polyethylene Glycol
(2000,4000,6000,8000,10000,20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, stearic acid, sodium stearate, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyethers one or more composition.
(1) takes by weighing an amount of Icing Sugar or other substrate, add water or binding agent, make suitable soft material, add the ingredient that contains ceftazidime, stir, cut apart, shaping, drying.
(2) take by weighing an amount of Icing Sugar or other substrate, add the ingredient that contains ceftazidime, add water or binding agent, stir, granulate, drying is shaped on tablet machine.
(3) take by weighing an amount of Icing Sugar or other substrate, add the ingredient that contains ceftazidime,,, on tablet machine, be shaped then through cooled and solidified through being heated as the miscible or miscible state of semi-molten of fusion.
(4) take by weighing an amount of Icing Sugar or other substrate,, be cooled to 70-100 ℃, add the ingredient that contains ceftazidime, stir, on tablet machine, be shaped through being heated as the miscible or miscible state of semi-molten of fusion.
2. the preparation of drop pill: proportionally ceftazidime is mixed with substrate; Substrate is by containing Polyethylene Glycol
(2000,4000,6000,8000,10000,20000), one or more one-tenth in polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, stearic acid, sodium stearate, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyethers are grouped into.Adopt water-bath, oil bath or other mode of heating, mixed material is heated to fusion, stir, insert on the drop pill machine, splash in 40 →-15 ℃ the condensing agent with suitable speed.Condensing agent can be any one or a few in liquid paraffin, methyl-silicone oil, the vegetable oil.
3. the preparation of confection: proportionally ceftazidime is mixed with substrate; Matrix filler is to be grouped into by one or more the one-tenth that contains in sucrose, maltose, dextrinose, dextrinose oligosaccharide, panose, cottonseed sugar, stachyose, oligofructose, glucose, fructose, lactose, inulin, protein sugar, stevioside, xylitol, maltose alcohol, sorbitol, gelatinized corn starch, syrup, the maltose etc.
Take by weighing an amount of Icing Sugar or other substrate heat fused, be cooled to uniform temperature then after, add the ingredient contain ceftazidime, stir, make into the plasticity magma, cut apart extrusion molding;
4. capsular preparation: proportionally ceftazidime is mixed with substrate; Substrate is by containing Icing Sugar, gelatin, glycerol, arabic gum, starch, dextrin, lactose, glucose, mannitol, calcium sulfate, calcium hydrogen phosphate, tricalcium phosphate, gelatinized corn starch, syrup, maltose, gelatine size, polyvinylpyrrolidone, Polyethylene Glycol, methylcellulose, carboxymethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, sucrose dextrin copolymer, Polyethylene Glycol
1500～20000, among stearic acid, sodium stearate, calcium stearate, sodium chloride, fumaric acid, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyoxyethylene stearate 40 esters, polyethers, carboxymethyl starch sodium, silica sol, succinic acid, xanthan gum, aspartame, mannitol, silica gel, silicon dioxide, saccharin sodium, carbomer 934 P, carbomer 971P and carbomer 974P etc. one or more become to be grouped into
Take by weighing an amount of substrate, add the ingredient that contains ceftazidime, stir, granulate capsule charge;
5. the preparation of tablet: proportionally ceftazidime is mixed with substrate; Substrate is by containing Icing Sugar, gelatin, glycerol, arabic gum, starch, dextrin, lactose, glucose, mannitol, calcium sulfate, calcium hydrogen phosphate, tricalcium phosphate, gelatinized corn starch, syrup, maltose, gelatine size, polyvinylpyrrolidone, Polyethylene Glycol, methylcellulose, carboxymethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose, sucrose dextrin copolymer, Polyethylene Glycol
1500～20000, among stearic acid, sodium stearate, calcium stearate, sodium chloride, fumaric acid, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyoxyethylene stearate 40 esters, polyethers, carboxymethyl starch sodium, silica sol, succinic acid, xanthan gum, aspartame, mannitol, silica gel, silicon dioxide, saccharin sodium, carbomer 934 P, carbomer 971P and carbomer 974P etc. one or more become to be grouped into
Take by weighing an amount of substrate, add the ingredient that contains ceftazidime, stir, granulate, tabletting is shaped on tablet machine;
Ceftazidime buccal lozenge of the present invention is compared with existing general formulation has following benefit:
1) the ceftazidime concentration at raising position, sick limit improves its antibacterial ability.Medicine dissolves in the saliva in the oral cavity, enters around the oral cavity, pharyngeal and pharyngeal tonsil position.These medicines do not pass through hemodilution, form high local concentrations, strengthen antibacterial ability.
2) rapid-action.Medicine is behind dissolved in oral cavity, and effect and pathological tissues have saved the time limit that absorbs distribution immediately.
3) convenient drug administration.To the ceftazidime of need,, directly act on position, disease limit then by sucking the messenger drug thing at dissolved in oral cavity through the parenteral route administration.
[specific implementation method]
By following concrete embodiment, can further understand the present invention, but following example not a limitation of the invention.
Embodiment 1-ceftazidime confection
Prescription: ceftazidime sodium 125g, sucrose 853g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, carbomer 934 P 2g, 1000 of amount of formulation.
Method: preparation ceftazidime sodium 125g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, carbomer 934 P 2g mixture grind, and cross 20 purpose sieves.Get sucrose 853 grams, be heated to 140 ℃ of fusings, be cooled to 85 ℃, add the mixture after sieving, stirred fast 10 minutes, place extrusion molding on the product shaping machine, every buccal tablet weighs 1 gram.Measure the disintegration of ceftazidime sodium confection in 37 ℃ of 900ml water and the dissolution during complete disintegrate then.
The result: be 6-9 minute disintegration, and fully the dissolution during disintegrate is 93%-99%.
Embodiment 2-low sugar ceftazidime confection (1)
Prescription: ceftazidime sodium 125g, sucrose 203g, oligofructose 300g, xylitol 300g, inulin 50g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, carbomer 934 P 2g, 1000 of amount of formulation.
Method: preparation ceftazidime sodium 125g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, carbomer 934 P 2g mixture grind, and cross 20 purpose sieves.Get sucrose 203g, oligofructose 300g, xylitol 300g, inulin 50g, mix, be heated to 140 ℃ of fusings, be cooled to 85 ℃, add the ceftazidime sodium 125g after sieving, stirred fast 10 minutes, place extrusion molding on the product shaping machine, every buccal tablet weighs 1 gram.Measure the disintegration of ceftazidime sodium confection in 37 ℃ of 900ml water and the dissolution during complete disintegrate then.
The result: be 6-13 minute disintegration, and fully the dissolution during disintegrate is 93%-100%.
Embodiment 3-low sugar ceftazidime buccal tablet (1)
Prescription: ceftazidime sodium 125g, gelatin 240g, glycerol 60g, water 60g, oligofructose 133g, xylitol 300g, inulin 50g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, magnesium stearate 10g, carbomer 934 P 2g, 1000 of amount of formulation.
Method: preparation gelatin 240g, glycerol 60g, water 60g mixed-matrix, drying adds ceftazidime sodium 125g, oligofructose 133g, xylitol 300g, inulin 50g, citric acid 10g, food pigment-40 0.1g again, mannitol 10g, carbomer 934 P 2g mixture, grind, cross 20 purpose sieves, granulate 60 ℃ of dryings with the second alcohol and water, add 10 gram magnesium stearate then, mixing places extrusion molding on the tablet machine, and every buccal tablet weighs 1 gram.Measure the disintegration of ceftazidime sodium lozenge in 37 ℃ of 900ml water and the dissolution during complete disintegrate then.
The result: be 9-15 minute disintegration, and fully the dissolution during disintegrate is 92%-97%.
Embodiment 4-ceftazidime buccal tablet
Prescription: ceftazidime sodium 125 grams, hypromellose 100 grams, Polyethylene Glycol
6000775 grams, aspartame 0.1 gram, 1000 of amount of formulation.
Method: preparation hypromellose 100 grams, Polyethylene Glycol
6000775 grams, aspartame 0.1 gram mixed-matrix, heat fused is cooled to 80 ℃, adds ceftazidime sodium 125 grams, stirring and evenly mixing, room temperature is cooled to solidifies, and granulates, and places extrusion molding on the tablet machine, and every buccal tablet weighs 1 gram.Measure the disintegration of ceftazidime sodium sodium lozenge in 37 ℃ of 900ml water and the dissolution during complete disintegrate then.
The result: be 25-31 minute disintegration, and fully the dissolution during disintegrate is 91%-98%.
Embodiment 5-low sugar ceftazidime confection (2)
Prescription: ceftazidime sodium 125g, sucrose 203g, oligofructose 300g, xylitol 300g, inulin 50g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, carbomer 934 P 2g, 1000 of amount of formulation.
Method: preparation ceftazidime sodium 125g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, carbomer 934 P 2g mixture grind, and cross 20 purpose sieves.Get sucrose 203g, oligofructose 300g, xylitol 300g, inulin 50g, mix, be heated to 140 ℃ of fusings, be cooled to and solidify, granulate, grind, cross 20 purpose sieves, add the ceftazidime sodium mixture after sieving, stirred fast 10 minutes, place extrusion molding on the product shaping machine, every heavy 1 gram.Measure the disintegration of ceftazidime sodium confection in 37 ℃ of 900ml water and the dissolution during complete disintegrate then.
The result: be 6-11 minute disintegration, and fully the dissolution during disintegrate is 92%-100%.
The preparation of embodiment 6-ceftazidime buccal drop pills
Method: taking polyethylene glycol 4,000 8.3 restrains respectively, polyethylene glycol 6000 7 grams, polyoxyethylene stearate 40 esters 1 gram, carbomer 2 grams, betacyclodextrin 1 gram, poloxamer 0.5 gram, carboxymethyl starch sodium 0.5 gram, stearic acid 0.1 gram, sodium stearate 0.1 gram, glycerin gelatine 0.1 gram, glyceryl monostearate 0.1 gram, Lac 0.1 gram, polyoxyethylene monostearate 0.1 gram, polyethers 0.1 gram, mix homogeneously, add ceftazidime sodium raw materials powder 30 grams again, fully mix, adopt electrically heated mode with the supplementary material mixture heated that makes to molten condition, adopt homemade special drilling pill machine, regulate its water dropper temperature and make it remain on 85 ℃ (error＜2%); With the methyl-silicone oil is condensing agent, the refrigeration control system of regulating the drop pill machine makes the temperature of condensing agent remain on 20 →-5 ℃ (error＜5%), the system of dripping, wait to take out behind the type of being shrunk to, remove the surface condensation agent, dry, make the drop pill that contains ceftazidime sodium 30mg/ grain, carry out then rounding rate (%), dissolve scattered time limit (minute), the mensuration of the ball method of double differences different (%) and hardness, the rounding rate is 80% as a result, and dissolve scattered time limit 3-6 minute, the ball method of double differences was different from 10%, hardness is qualified, and fully the dissolution during disintegrate is 92%-97%.
Embodiment 7-low sugar ceftazidime buccal tablet (2)
Prescription: ceftazidime sodium 125g, gelatin 240g, glycerol 40g, water 60g, oligofructose 180g, xylitol 192g, inulin 50g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, magnesium stearate 10g, hypromellose 143 grams, 1000 of amount of formulation.
Method: preparation gelatin 240g, glycerol 40g, water 60g mixed-matrix, drying adds ceftazidime sodium 125g, oligofructose 180g, xylitol 192g, inulin 50g, citric acid 10g, food pigment-40 0.1g again, mannitol 10g, hypromellose 143 gram mixture, grind, cross 20 purpose sieves, granulate 60 ℃ of dryings with the second alcohol and water, add 10 gram magnesium stearate then, mixing places extrusion molding on the tablet machine, and every buccal tablet weighs 1 gram.Measure the disintegration of ceftazidime sodium lozenge in 37 ℃ of 900ml water and the dissolution during complete disintegrate then.
The result: be 20-27 minute disintegration, and fully the dissolution during disintegrate is 92%-96%.
Embodiment 8-low sugar ceftazidime confection (3)
Prescription: ceftazidime sodium 125g, sucrose 83g, oligofructose 170g, xylitol 300g, inulin 50g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, hypromellose 252 grams, 1000 of amount of formulation.
Method: preparation ceftazidime sodium 125g, citric acid 10g, food pigment-40 0.1g, mannitol 10g, hypromellose 252 gram mixture grind, and cross 20 purpose sieves.Get sucrose 83g, oligofructose 170g, xylitol 300g, inulin 50g, mix, be heated to 140 ℃ of fusings, be cooled to room temperature and solidify, granulate, grind, cross 20 purpose sieves, add the mixture after sieving, stirred 10 minutes fast, place extrusion molding on the product shaping machine, every buccal tablet weighs 1 gram.Measure the disintegration of ceftazidime sodium confection in 37 ℃ of 900ml water and the dissolution during complete disintegrate then.
The result: be 41-48 minute disintegration, and fully the dissolution during disintegrate is 93%-98%.
Claims (10)
1. one kind is the buccal lozenge of main ingredient with ceftazidime, is made of its Chinese medicine ingredient that includes ceftazidime and substrate: substrate=1: 1-1: 30.
2. the buccal lozenge of ceftazidime according to claim 1, it is characterized in that: described buccal lozenge is used for through port intracavity and sublingual administration administration.
3. the buccal lozenge of ceftazidime according to claim 1 is characterized in that: described buccal lozenge is clinical to be used for but to be not limited to treat pharyngitis, pharyngoamygdalitis and oral cavity infection.
4. the buccal lozenge of antibiotics according to claim 1, it is characterized in that: described ceftazidime is ceftazidime and salt derivative thereof.
5. the buccal lozenge of ceftazidime according to claim 1, it is characterized in that: described preparation type includes but not limited to buccal tablet, drop pill, confection, capsule, tablet.
6. the described a kind of preparation method that contains the buccal tablet of ceftazidime of claim 5, it is characterized in that: described buccal tablet is through being heated as the miscible or miscible state of semi-molten of fusion by the ingredient that contains ceftazidime and substrate, then through cooled and solidified, and then make described buccal tablet, its mesostroma is by containing Polyethylene Glycol
(2000,4000,6000,8000,10000,20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, stearic acid, sodium stearate, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyethers one or more one-tenth be grouped into.
7. the described a kind of preparation method that contains the buccal tablet of ceftazidime of claim 5, it is characterized in that: described buccal tablet is by ingredient that contains ceftazidime and substrate mix homogeneously, granulates drying, on tablet machine, be shaped, and then make described buccal tablet.
8. a kind of preparation method of drop pill according to claim 5, it is characterized in that: proportionally ceftazidime is mixed with substrate, adopt water-bath, oil bath or other mode of heating, mixed material is heated to fusion, stir, insert on the drop pill machine with suitable speed, splash in 40 →-15 ℃ the condensing agent and be shaped, its mesostroma is by containing Polyethylene Glycol
(2000,4000,6000,8000,10000,20000), one or more one-tenth in polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, stearic acid, sodium stearate, glycerin gelatine, glyceryl monostearate, Lac, polyoxyethylene monostearate, polyethers are grouped into.
9. the described a kind of preparation method that contains the confection of ceftazidime of claim 5, it is characterized in that: described confection be earlier with substrate through being heated as the miscible state of fusion, then through being cooled to semi-solid, add the ingredient that contains ceftazidime then, stirring and evenly mixing, make into the plasticity magma, cut apart, extrusion molding.
10. according to claim 6,7,8 and 9 described preparation methoies, it is characterized in that: described substrate also can add one or more medicinal slow releasing agent and conventional coloring agent, correctives, spice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610152610 CN1939264A (en) | 2005-09-26 | 2006-09-25 | Oral preparation containing ceftazidime and its making method |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510104990 | 2005-09-26 | ||
| CN200510104990.4 | 2005-09-26 | ||
| CN 200610152610 CN1939264A (en) | 2005-09-26 | 2006-09-25 | Oral preparation containing ceftazidime and its making method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1939264A true CN1939264A (en) | 2007-04-04 |
Family
ID=37957977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610152610 Pending CN1939264A (en) | 2005-09-26 | 2006-09-25 | Oral preparation containing ceftazidime and its making method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1939264A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103980480A (en) * | 2013-02-07 | 2014-08-13 | 杨子剑 | Preparation and use of drug grafted polymer |
| CN106420658A (en) * | 2016-09-23 | 2017-02-22 | 临沂草之美医药科技有限公司 | Ceftazidime capsule for treating surgical infection |
-
2006
- 2006-09-25 CN CN 200610152610 patent/CN1939264A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103980480A (en) * | 2013-02-07 | 2014-08-13 | 杨子剑 | Preparation and use of drug grafted polymer |
| CN103980480B (en) * | 2013-02-07 | 2018-08-17 | 杨子剑 | A kind of preparation and use of the polymer of grafting drug |
| CN106420658A (en) * | 2016-09-23 | 2017-02-22 | 临沂草之美医药科技有限公司 | Ceftazidime capsule for treating surgical infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3452018A2 (en) | Effervescent formulations comprising cefaclor and clavulanic acid as active agents | |
| CN1939264A (en) | Oral preparation containing ceftazidime and its making method | |
| CN1939285A (en) | Oral preparation containing cephradine and its making method | |
| CN1939262A (en) | Oral preparation containing cephaampi and its making method | |
| CN1939263A (en) | Oral preparation containing cefaclor and its making method | |
| CN1939260A (en) | Oral preparation containing gentamicin and its making method | |
| CN1939261A (en) | Oral preparation containing cefoperazone schubatain and its making method | |
| CN1939258A (en) | Oral preparation containing penicillin V potassium and its making method | |
| CN1939267A (en) | Oral preparation containing amoxicillin clatrenoin and its making method | |
| CN1939273A (en) | Oral preparation containing rokuromycin and its making method | |
| CN1939276A (en) | Oral preparation containing paracillin and its making method | |
| CN1939266A (en) | Oral preparation containing amoxicillin flucloxacillin and its making method | |
| CN1943553A (en) | Oral preparation containing ceftriaxone and its preparing method | |
| CN1939272A (en) | Oral preparation containing clarithromycin and its making method | |
| CN101152144A (en) | Buccal preparation containing levorotation ofloxacin and method for preparing the same | |
| CN1939265A (en) | Oral preparation containing cefoperazone and its making method | |
| CN1939275A (en) | Oral preparation containing mezlocillin and its making method | |
| CN1939270A (en) | Oral preparation containing ampicillin schubatain and its making method | |
| CN1846702A (en) | Dispersed cefditoren pivoxil tablet and its prepn process | |
| CN1939269A (en) | Oral preparation containing ampicillin and its making method | |
| CN1939300A (en) | Oral preparation containing amocillin and its making method | |
| CN1939259A (en) | Oral preparation containing penicillin G and its making method | |
| CN1939274A (en) | Oral preparation containing mediromycin and its making method | |
| CN1939268A (en) | Oral preparation containing azithromycin and its making method | |
| WO2011078820A1 (en) | Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070404 |